BDENZA 80 mg contains enzalutamide, a next-generation oral androgen receptor inhibitor used in the treatment of prostate cancer. It is specifically indicated for men with metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Enzalutamide works by blocking the action of male hormones (androgens) that fuel the growth of prostate cancer cells.

Mechanism of Action
Enzalutamide works by binding directly to the androgen receptor, preventing its activation by testosterone and other androgens. This blocks the receptor from:

1. Moving into the cell nucleus

2. Binding to DNA

3. Activating genes that promote cancer cell survival and proliferation

   Uses
   BDENZA 80 mg is used in the management of:

   • Metastatic castration-resistant prostate cancer (mCRPC)

   • Non-metastatic castration-resistant prostate cancer (nmCRPC)

   • Metastatic hormone-sensitive prostate cancer (mHSPC) in some treatment regimens

     Adverse Effects
     While generally effective and well-tolerated, enzalutamide can cause several side effects, particularly related to nervous system and metabolic changes.

     Common side effects include:

     • Fatigue or feeling unusually tired

     • High blood pressure

     • Hot flashes

     • Joint or back pain

     • Decreased appetite or weight loss